Non-bericht. Leuk hoor (versteviging of verlenging van) die patentjes, maar wat mot je ermee als er geen belangstelling is.
Bericht verscheen trouwens in de GTC-vorm al op 20 mei en werd ook op dit forum geplaatst, dus elke ophef is mosterd na de maaltijd.
20 mei 2011 om 16:46u
GTC Biotherapeutics, Inc., a LFB Group Company, Granted Protection until 2027 on Broad Transgenic Protein Production Patent, and is Also Granted New Patent on Recombinant Anti-Thrombin Produced Transgenically
FRAMINGHAM, Mass.--(BUSINESS WIRE)-- GTC Biotherapeutics, Inc. (GTC) (a wholly-owned subsidiary of LFB Biotechnologies S.A.S., Les Ulis, France), announced today that the United States Patent and Trademark Office (USPTO) granted (to GTC) a patent covering DNA constructs for the production of any therapeutic protein in the milk of any transgenic animal. This “Broad DNA” patent extends to 2027. GTC’s intellectual property position also includes a United States Patent extending to 2021 covering methods for the production of any therapeutic protein in the milk of non-human transgenic mammals. With this event, GTC’s intellectual property (estate) includes patents in the United States expiring as late as 2027 covering DNA constructs and methods for the production of any therapeutic protein in the milk of transgenic mammals.
Commenting on the news, William Heiden, GTC CEO stated “We are very pleased by the news granting us further protection for our core technology through 2027. We have worked very hard over many years perfecting the technology and this news reinforces GTC’s position as the world leader in transgenic therapeutic protein production. We are now leveraging the platform to develop low-cost recombinant forms of a number of plasma-derived proteins, bio-better monoclonal antibodies, as well as novel antibodies.”
Christian Bechon, CEO of LFB Group stated “Economic assessments of new health technologies are becoming more and more prevalent in the biopharmaceutical industry. The news of enhanced patent protection for GTC’s core technology, which delivers the highest quality protein therapeutics at lower cost, is extremely important for the LFB Group.”
In addition, GTC is announcing that it has been granted another United States patent for its lead product ATryn® (recombinant human antithrombin). ATryn was the first – and is still the only, transgenically produced therapeutic protein approved by both the FDA and EMA authorities. The claims of this new patent relate to a method of treating subjects having an antithrombin III deficiency or inflammation